Clinical Trials

88 enrolled

Phase 1/2 Active not recruiting

Liver Neoplasms

NCT05286801 2026-04-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

86 enrolled

Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT05411081 2026-04-13

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

200 enrolled

Phase 1 Active not recruiting

Carcinoma, Renal Cell

NCT05595460 2026-04-13

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

21 enrolled

Thoracic

SCLC,Extensive Stage

NCT04180072 2026-04-09

Atezolizumab Plus Bevacizumab With HCC and HBV Infection

Phase NA Active not recruiting

51 enrolled

Carcinoma, Hepatocellular

NCT03093922 2026-04-07

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

32 enrolled

Carcinoma, Transitional Cell

NCT04138628 2026-04-07

TOMBOLA

154 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT04560972 2026-04-07

LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

3 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

211 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

49 enrolled

Tumor-Agnostic

Neoplasms

NCT05047250 2026-04-03

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04589845 2026-04-02

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

920 enrolled 2 FDA

Other solid neoplasm

Solid Tumors

NCT04820179 2026-04-02

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT03614949 2026-04-01

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

21 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04729959 2026-04-01

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

59 enrolled

CNS

Astrocytoma, Glioblastoma

NCT04660344 2026-03-27

IMvigor011

761 enrolled

Phase 1 Active not recruiting

Muscle-invasive Bladder Cancer

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Dermatologic

Skin Neoplasms

NCT04637594 2026-03-20

IMAGINE

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT04102098 2026-03-19

IMbrave050

668 enrolled 11 charts

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT05142696 2026-03-17

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

24 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors